Advisory Board

      Collapse All | Expand All
      • Introduction to our Advisory Board

        The EpiSoft Advisory Board was formed in mid 2007 to assist us with our company's strategic direction. We sought the assistance of three of Australia's foremost thought leaders in the fields of health informatics, corporate medicine, medical research and pharmaceutical industry business development. Our Advisory Board members provide their unique and complementary insights into our strategy for growth.

        The advice they have provided to us has been invaluable in shaping the EpiSoft business and we look forward to a long association with our Advisory Board members listed below.

      • Dr Michael Legg

        Dr Michael Legg (BSc(Hons) MCom(BIS) PhD FAICD FACHI MACS PCP) has led more than 30 successful projects since the establishment of his consultancy in 2000. Trained as a researcher in experimental pathology, Dr Legg has had 20 years as a successful leader in the health industry, with 15 years in CEO level positions. He has extensive experience in corporate medicine including as Director Developments - Pathology, Health Care of Australia, and prior to that, General manager of Southern Pathology, winners of the Australian Quality Award for Business Excellence. Prior to this, he was Director of Medicheck, the Sydney Square Diagnostic Breast Clinic and Breasthealth.

        He is current Chairman of the Health Informatics Society of Australia and has been an Adjunct Professor in Health Informatics with Central Queensland University and a Professorial Fellow with the Centre for Health Informatics Research at the University of Wollongong.

        Michael has served on many national committees including the National Health Information Group Sub-Committee for Informatics Standards (ICTSC) and its predecessor the National Health Information Standards Committee (NHISAC0, the Australian Health Information Council's subcommittee on Electronic Decision Support (AHIC-EDS), and the HealthConnect Stakeholder Reference Group. He was Vice President of the Australian Association of Pathology Practices (AAPP), member of the Quality Use of Pathology Committee (QUPC), the RCPA Informatics Working Group and the Pathology Services Table Committee (PSTC).

      • Emeritus Professor Graham Macdonald

        Graham is a graduate of the University of Sydney who trained in nephrology and high blood pressure research at St Mary's Hopsital, London, before returning to take up a senior lectureship at the University of NSW and chairmanship of the Department of Nephrology at the Prince Henry Hospital in 1974. This entailed responsibilities for undergraduate and postgraduate teaching, clinical care and basic and clinical research. His main research interests were in kidney hormones, high blood pressure and vascular disease, including non-pharmacological control of high blood pressure, interaction of vascular risk factors, pregnancy-induced hypertension, psycho-social outcomes of dialysis, control of thirst and drinking behaviour and novel mechanisms of control of renal sodium excretion originating in the upper intestinal tract.

        Professor Macdonald retired from the University in 1998 and spent the next nine years working for the pharmaceutical company Merck Sharp & Dohme (Australia), initially as Medical Director until mid 2001, then as external Licensing Co-ordinator until he retired from that position in 2007. In this role, he identified licensing and partnership opportunities for Merck & Co among Australasian biotechnology companies and research institutes.

        Graham has extensive experience of clinical trial design and renal service delivery. From 1991 to 1993, he was chairman of the Medical and Scientific Advisory Committee and a member of the board of the Australian Kidney Foundation (now Kidneys Health Australia). during this time, he oversaw the establishment of the Foundation's Education Division.

        Since his retirement from Merck Sharp & Dohme, Graham has been engaged in biotechnology consulting projects and is Chairman of the boards of two early stage biotechnology companies. He also chairs the Pharmaceuticals Education Council which is developing solutions to skills shortages in the Australian biopharmaceutical workforce.

      • Mr Rob Love

        Rob has a background in pharmaceutical industry marketing and business development. In the latter role for Merck Sharp & Dohme (Australia), he reviewed and participated in a range of strategic acquisition opportunities for the company. He also managed the process of the company exiting the manufacture of medicines still in use when no longer considered profitable. He was responsible (together with Michael Hurse of EpiSoft) for leading MSD through the most comprehensive strategic planning exercise ever undertaken by the Australian subsidiary. This future mapping project identified a number of differentiating opportunities, some of which the company has subsequently implemented.

        Rob left the pharmaceutical industry to become senior advisor to the General manager of CCH and in this role, gained first hand experience in software and information services business development and marketing. He subsequently returned as a management consultant to the pharmaceutical industry advising a range of clients on strategic matters, in particular with a marketing and business development focus. He was appointed as Director Operations and Business Development to Abbott (Australasia) during 2008. Rob has academic qualifications in marketing and an MBA.